Otrivin is owned by Haleon (the United Kingdom, LSE: HLN), which was separated from GSK on 18 July 2022.[1][2] Before Haleon, Otrivin was owned by GSK from 2015 to 2022.[2]
Otrivin is a nasal decongestant spray using xylometazoline, launched in 1953 and sold in more than seventy countries. It is one of the largest brands in a category otherwise dominated by local names.
What Haleon's annual report says about Otrivin
Sentences about Otrivin from Haleon's latest annual filing[1], copied word for word.
Innovation-led premiumisation: In North America, we launched our new nasal mist technology under the Theraflu brand following its success with Otrivin, which is driving strong market gains.
Activity examples Key growth driver and 2025 activities Market driver(s) Innovation-led premiumisation Continued the global expansion of our superior Otrivin Nasal Mist.
We are progressing with the transition to using mass balance bio-based resins for the production of Otrivin nasal sprays, which delivered incremental virgin petroleum-based plastic savings in 2025.
How often Haleon names Otrivin in its annual report
A plain count of the times the name appears in the text of each annual report, not counting the start of a sentence. A brand that an owner writes about more is usually one it treats as central. The brand is named less often than it was three years earlier.
Haleon is a publicly listed company headquartered in Weybridge, United Kingdom, founded in 2022. Brandtree records 8 brands under its control, and it is listed as LSE: HLN and NYSE: HLN.
Haleon is the consumer health business demerged from GSK in July 2022, having earlier absorbed Pfizer's consumer health portfolio through a joint venture. It is the largest standalone consumer health company in the world, built on oral health, pain relief, respiratory health and vitamins.
Brandtree records a controlling owner for 128 brands that began in Switzerland.
35 of them (27%) are now controlled by a company headquartered in another country, Otrivin among them.
GSK demerged its consumer healthcare business as Haleon, listing it in London and New York in July 2022. The business already contained Pfizer's consumer health portfolio, contributed to a joint venture in 2019, which is how Advil and Centrum came to sit alongside Sensodyne and Panadol.
The parent company of Otrivin is Haleon, a publicly listed company headquartered in the United Kingdom.
Is Otrivin Swiss or British?
⌄
Otrivin originated in Switzerland in 1953, but it is owned today by Haleon, which is headquartered in the United Kingdom. So Otrivin is a Swiss-origin brand under British ownership.
Since when has Haleon owned Otrivin?
⌄
Haleon has owned Otrivin since 18 July 2022.
Who owned Otrivin before Haleon?
⌄
Before Haleon, Otrivin was owned by GSK from 2015 until 2022.
Is Otrivin still owned by Haleon?
⌄
Yes. As of 9 October 2026, Otrivin is still owned by Haleon. The ownership record was last checked against primary sources on that date.
Sources (2) & corrections
Last verified . Every ownership fact above is backed by one of these primary documents. Numbers in brackets in the text refer to this list.
Brandtree needs to remember this choice and does not set any other cookie unless you accept.
If you choose “Accept all”, we also use Google Analytics cookies to count visits and see which pages help, so we can improve the site.
If you choose “Accept required”, no analytics cookie is set. Google Analytics still receives a cookieless ping with the page address and your IP address. No advertising is used either way. Privacy policy